XtalPi Advances KQTD-126 Into FDA IND Review
Boston, Massachusetts, and Shenzhen, China, September 24, 2026 XtalPi has reached a significant milestone in its proprietary drug-development pipeline...
gastrointestinal disease
Advertisement
Eupraxia Reports Durable EoE Symptom Improvements With EP-104GI
VANCOUVER, British Columbia, August 13, 202 Eupraxia Pharmaceuticals Inc. reported new symptom-response data from the ongoing Phase 1b/2a portion...
Vedanta Biosciences Secures $60M to Advance Phase 3 VE303
CAMBRIDGE, Mass., August 6, 2026 Vedanta Biosciences announced it has secured $60 million in funding to accelerate development of...
Lilly’s Retevmo Cuts Recurrence Risk by 83% in NSCLC
INDIANAPOLIS, Indiana, May 31, 2026 Eli Lilly and Company has announced groundbreaking results from the pivotal Phase 3 LIBRETTO-432...
Hanmi and Lilly Strike $1.26 Billion Deal for Promising GLP-2 Drug Candidate Sonefpeglutide
SEOUL, South Korea, June 1, 2026 Hanmi Pharm. Co., Ltd. has entered into a landmark global licensing agreement with...
Advertisements
Ironwood Wins FDA Approval for Pediatric LINZESS
BOSTON — May 27, 2026 Ironwood Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved an...
EnteroBiotix Secures £19M for Phase 2b IBS-C Trial
GLASGOW, Scotland, April 29, 2026 EnteroBiotix Limited has announced the successful completion of a £19 million ($25 million) financing...
Cristcot NDA Accepted for ngHCA in Ulcerative Colitis
Austin, Texas, USA, April 21, 2026 In a significant regulatory milestone for gastrointestinal therapeutics, Cristcot HD LLC has announced...
Advertisement
